EDAN Presented a Regional Development Blueprint for the Delegation from the Colombian Consulate

The Consul General of Colombia in Guangzhou, Hernan Vargas Martin, led a delegation to visit the headquarter of Edan Instruments, Inc. (300206.SZ) in Shenzhen, and exchanged development strategies and actions of Latin American market with Alex You, Global Marketing & Strategic Operations Director, and Eric Li, Senior Regional Manager of EDAN.

“After more than a decade of exploration, the Latin American market has developed into one of EDAN’s most important markets worldwide,” Said Alex, “In particular in Colombia, important outcomes have been achieved including the fruitful cooperation between top medical institutions such as the Central Military Hospital of Bogotá and Clinica Bonnadona Prevenir.”

EDAN initiated a strong long-term cooperation with Colombian medical institutions in 2007. Over 10,000 medical devices have been dispatched in Colombia during the pandemic, and to date, the company has supplied more than 5,000 medical devices annually to the Colombian market.

To further benefit the local users and build a closer relationship, Edan Diagnostics Peru S.A.C. (EDAN Peru) was newly established in Lima, serving as the Latin American operation hub of EDAN, providing timely pre-sale and post-sale support, especially for the Andean Community member countries like Peru, Colombia, Bolivia, Ecuador, etc.

“It’s delighted to notice that EDAN has further development agenda in the region, including establishing more subsidiaries for immediate service and support within reach,” The Consul General pointed out the outstanding growth opportunities in the Andean region and highlighted how collaboration helps achieve future growth, “Colombia has a distinct advantage in labor, tariffs and taxes, which is also in line with EDAN’s future development plans in Latin America. We will also provide more support to well-known medical device brands like EDAN to create a more business-friendly environment.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”